Marta Surman Selected Research

Leukemia

1/2023

Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marta Surman Research Topics

Disease

2	Infections 01/2023 - 01/2021
1	Fever of Unknown Origin 01/2023
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023
1	Lymphoma (Lymphomas) 01/2023
1	Leukemia 01/2023
1	Residual Neoplasm 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021
1	Primary Immunodeficiency Diseases 01/2021
1	Adenocarcinoma 03/2017

Drug/Important Bio-Agent (IBA)

1	EnzymesIBA 01/2023
1	Gemtuzumab (Mylotarg)FDA Link 01/2023
1	blinatumomabIBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 03/2017

Therapy/Procedure

1	Bridge Therapy 01/2022
1	Hematopoietic Stem Cell Transplantation 01/2022
1	Therapeutics 01/2021